Show simple item record

Optimising the duration of adjuvant trastuzumab in early breast cancer in the UK

dc.contributor.authorEarl, H. M.
dc.contributor.authorHiller, L.
dc.contributor.authorDunn, J.
dc.contributor.authorMacpherson, I.
dc.contributor.authorRea, D.
dc.contributor.authorHughes-Davies, L.
dc.contributor.authorMcAdam, K.
dc.contributor.authorHall, P.
dc.contributor.authorMansi, J.
dc.contributor.authorWheatley, D.
dc.contributor.authorAbraham, J. E.
dc.contributor.authorCaldas, C.
dc.contributor.authorGasson, S.
dc.contributor.authorO'Riordan, E.
dc.contributor.authorWilcox, M.
dc.contributor.authorMiles, D.
dc.contributor.authorCameron, D. A.
dc.contributor.authorWardley, Andrew M
dc.date.accessioned2020-09-16T11:57:55Z
dc.date.available2020-09-16T11:57:55Z
dc.date.issued2020en
dc.identifier.citationEarl HM, Hiller L, Dunn J, Macpherson I, Rea D, Hughes-Davies L, et al. Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK. Clinical Oncology. 2020.en
dc.identifier.pmid32723485en
dc.identifier.doi10.1016/j.clon.2020.07.006en
dc.identifier.urihttp://hdl.handle.net/10541/623242
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.clon.2020.07.006en
dc.titleOptimising the duration of adjuvant trastuzumab in early breast cancer in the UKen
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK;en
dc.identifier.journalClinical Oncologyen
dc.description.noteen]
refterms.dateFOA2020-09-16T13:47:36Z


Files in this item

Thumbnail
Name:
ClinOnc optimising.pdf
Size:
514.5Kb
Format:
PDF
Description:
From UNPAYWALL
Download

This item appears in the following Collection(s)

Show simple item record